Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Interventions

pembrolizumab 1265 Specimen Handling 926 Magnetic Resonance Spectroscopy 830 Carboplatin 823 Cyclophosphamide 800 Cisplatin 723 Nivolumab 669 Paclitaxel 627 Radiotherapy 611 Gemcitabine 573 Biopsy 557 Bevacizumab 478 Dexamethasone 438 fludarabine 407 Docetaxel 380 venetoclax 368 Oxaliplatin 364 Capecitabine 358 Fluorouracil 355 atezolizumab 350 durvalumab 332 Rituximab 330 Drug Therapy 326 Doxorubicin 316 Radiosurgery 315 Standard of Care 309 Blood Specimen Collection 308 Pemetrexed 305 Ipilimumab 299 Radiation 286

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Serologic Tests × 1 year × Clear all

NCT06111963 2025-07-16

Role of Inflammatory Markers in Sepsis

National Cancer Institute, Egypt

Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡